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Abstract.  The fibroblast or heparin-binding growth 
factors (HBGFs) are thought to be modulators of cell 
growth and migration, angiogenesis, wound repair, 
neurite extension, and mesoderm induction. A better 
understanding of the structural basis for the different 
activities of these proteins should facilitate the devel- 
opment of agonists and antagonists of specific HBGF 
activities and identification of the signal transduction 
pathways involved in the mechanisms of action of 
these growth factors. Chemical modification studies of 
Harper and Lobb (Harper, J. W., and R.  R.  Lobb. 
1988. Biochemistry.  27:671-678)  implicated lysine 132 
in HBGF-1  (acidic fibroblast growth factor) as being 
important to the heparin-binding, receptor-binding, 
and mitogenic activities of the protein. We changed 
lysine 132 to a glutamic acid residue by site-directed 
mutagenesis of the human cDNA and expressed the 
mutant protein in Escherichia  coli to obtain sufficient 
quantities for functional studies. Replacement of this 
lysine with glutamic acid reduces the apparent affinity 
of HBGF-1 for immobilized heparin (elutes at 0.45  M 
NaC1 vs.  1.1  M  NaCI for wild-type). Mitogenic assays 
established two points:  (a) human recombinant I-IBGF-1 
is highly dependent on the presence of heparin for op- 
timal mitogenic activity, and (b) the change of lysine 
132 to glutamic acid drastically reduces the specific 
mitogenic activity of HBGF-1.  The poor mitogenic ac- 
tivity of the mutant protein does not appear to be due 
to a reduced affinity for the HBGF receptor. Similarly, 
the mutant HBGF-1  can stimulate tyrosine kinase ac- 
tivity and induce protooncogene expression. Differ- 
ences in the biological properties of the wild-type and 
mutant proteins were observed in transfection studies. 
Mutant HBGF-1  expression in transfected NIH 3T3 
cells did not induce the same transformed phenotype 
characteristic of cells expressing wild-type HBGF-1. 
Together these data indicate that different functional 
properties of I-IBGF-1 may be dissociated at the struc- 
tural level. 
T 
HE  heparin-binding  growth factor  (HBGF) l  family 
presently consists  of seven structurally related poly- 
peptides (3). The cDNAs for each have been cloned 
and sequenced. Two of the proteins,  HBGF-1 and HBGF-2, 
have been characterized under many different names, but 
most often as  acidic  and basic  fibroblast  growth factor, 
respectively.  Three sequence-related oncogenes have been 
identified; the hst oncogene was discovered based on its abil- 
ity to transform NIH 3T3 cells (9, 25, 38, 45); the int-2 on- 
cogene was  first  identified  as a  gene activated  by mouse 
mammary tumor virus (7,  10, 11) and the FGF-5 oncogene 
was identified using NIH 3T3 transformation assays (46, 47). 
Recently a gene termed FGF-6 was identified by screening 
a mouse cosmid library with a human hst probe under re- 
1. Abbreviation used in this paper: HBGF, heparin-binding growth factor. 
duced stringency and was shown to be capable of transform- 
ing NIH 3T3 cells (32). Finally, an epithelial cell-specific 
growth factor termed KGF or FGF-7 has been identified and 
its cDNA cloned and sequenced (13). 
Functions  associated with HBGF-1 and HBGF-2 include 
stimulation  of mitogenesis,  chemotaxis, mesoderm induc- 
tion, neurite extension,  and plasminogen  activator activity. 
These HBGFs also induce angiogenesis in vivo and acceler- 
ate wound repair (for reviews see references 3,  18, 27, 36). 
The mechanisms by which HBGFs promote these functions 
are poorly understood but may include activation of protein 
tyrosine kinase activity (8, 15, 20), phosphorylation ofphos- 
pholipase  C-3' (6), and activation of immediate-early gene 
transcription  (17). In addition,  both HBGF-1 and HBGF-2 
have been shown to be relatively resistant to degradation af- 
ter internalization by receptor-mediated  endocytosis (14, 24, 
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hours and large fragments (15,000 and 10,000 Mr for HBGF-1; 
16,000 Mr for HBGF-2) are detectable alter as many as 24 h. 
Further,  nuclear  or nucleolar localization  of HBGF-2 has 
been observed (2, 35). 
Despite the  identification  of additional  members  of the 
HBGF family and a broad range of cells and tissues that con- 
tain the growth factors, and despite the availability of large 
quantities of recombinant protein and increased knowledge 
of the broad spectrum  of activities of potential  biological 
significance that can be attributed to the HBGFs, relatively 
little is known regarding the relationship of these highly con- 
served structures to any of their known functions. Baird et 
al. (1) reported the synthesis of 25 peptides, which together 
encompass and overlap the entire sequence of HBGF-2 as de- 
scribed by Ueno et al.  (42).  They reported the identifica- 
tion of two functional domains in the primary structure of 
HBGF-2 based on the abilities of synthetic peptides to inter- 
act with HBGF receptor, bind radiolabeled heparin in a solid 
phase assay, and inhibit HBGF-2 stimulation of thymidine in- 
corporation into DNA. Using the numbering system of the 
authors (which does not correspond to full length HBGF-2) 
statistically significant functional activities could be assigned 
to peptides corresponding to residues 24-68 and 106-115 of 
HBGF-2. Similarly,  Schubert et al.  (39) demonstrated that 
peptides corresponding to residues 1-24, 24-68, and 93-120 
of I-IBGF-2  are  able to  stimulate  substratum  adhesion  of 
PC12 cells. We have shown that a synthetic peptide corre- 
sponding to residues 49-72 of I-IBGF-1 (using  numbering 
of 1-154  for full length  HBGF-1) is able to compete with 
I-IBGF-1 for heparin binding in a gel overlay assay (33). This 
region is homologous to one of the regions of I-IBGF-2 (res- 
idues 24-68) described above as possessing heparin-binding 
activity. 
To date, the most complete and informative studies docu- 
menting the effects of chemical modification of any I-IBGF 
on function are those of Harper and Lobb (19). Briefly, they 
were able to show that limited reductive methylation of bo- 
vine HBGF-I with formaldehyde and cyanoborohydride re- 
sulted in stoichiometric methylation only of lysine 132 (us- 
ing 1-154 numbering for full length HBGF-1). They reported 
90% modification of this residue, with 60% dimethylysine. 
The modified protein exhibited significantly reduced appar- 
ent affinity for immobilized heparin (eluted at •0.7  M NaC1 
vs. --1.2 M NaCl for unmodified HBGF-1), a fourfold reduc- 
tion in its ability to stimulate DNA synthesis in NIH 3T3 
fibroblasts and a similar reduction in its ability to compete 
with labeled ligand in a radioreceptor assay. A lysine residue 
is found at this position of HBGF-1 and HBGF-2 of all spe- 
cies characterized to date.  Together these data implicate a 
crucial role for lysine 132 in several of the known functions 
of HBGF-1. 
In this report we address the role of lysine 132 in HBGF-1 
function using site-directed mutagenesis of this position to 
a  glutamic  acid.  This  approach  offers several  advantages 
over chemical modification studies including (a) the ability 
to produce large quantities of the desired product, (b) elimi- 
nation of significant (although sub-stoichiometric) modifica- 
tion of other lysines,  and (c) allowing the introduction  of 
modified HBGF-1 into mammalian cells through transfection 
of cDNA expression vectors designed to produce the desired 
mutant.  Despite these advantages the importance of chemi- 
cal modification studies such as those of Harper and Lobb 
(19) should not be underestimated for they are extremely use- 
ful in the design of a rational approach to site-directed muta- 
genesis. The results described here demonstrate that replace- 
ment of lysine 132 of HBGF-1 with glutamic acid reduces 
significantly  its  apparent  affinity for immobilized heparin 
and its mitogenic capacity. However, the apparent affinity of 
the mutant for high affinity cell surface receptors appears un- 
altered. When assayed in the presence of heparin where the 
difference in wild-type and mutant HBGF-1 mitogenic activ- 
ity is most apparent, mutant HBGF-1 can stimulate tyrosine 
kinase activity and induce protooncogene expression. Func- 
tional differences between the wild-type and mutant HBGF-1 
are also apparent after transfection of cDNA expression vec- 
tors into NIH 3T3 fibroblasts. 
Materials and Methods 
Materials 
Heparin-Sepharose,  protein A-Sepharose, pKK233 expression vectors, and 
low molecular weight markers were purchased from Pharmacia Fine Chem- 
icais  (Piscataway,  NJ).  All  reagents  for  PAGE and  the  Mighty Small  Appara- 
tus  were from Hoefer Scientific Instruments (San Francisco,  CA). Reagents 
for reversed-phase  HPLC, amino acid analysis, and amino acid sequencing 
were purchased from Applied Biosystems, Inc. (Foster City, CA). Isotopes 
and the in vitro mutagenesis system were from Amersham Corp. (Arlington 
Heights, IL). The rabbit  polyclonal HBGF-l-specific antibody was provided 
by R. Friesel (American Red Cross, Rockville,  MD) and the rabbit poly- 
clonai anti-phospholipase CO' antibodies were provided by A. Zilberstein 
(Rorer Biotechnology, Inc., King of Prussia, FA). Tissue culture media and 
plasticware were purchased from Gibco Laboratories (Grand Island, NY). 
High molecular weight molecular markers were from Bio-Rnd Laboratories 
(Richmond, CA).  Endoproteinase ASP-N  and the random primer DNA 
labeling kit were from Boehringer Mannheim Biochemicals (Indianapolis, 
IN). Other chemicals were reagent grade. 
Construction of  pREC and p132E Prokaryotic 
Expression Plasmids 
The plasmid expressing wild-type HBGF-1 (corresponding to the a-form of 
endothelial cell growth factor (5), pREC, was kindly provided by R. Forongh 
(American Red Cross). This plasmid was constructed  by cloning synthetic 
oligonuclectide cassettes into the Nco I/Hind HI site of pKK233-2.  The 
plasmid expressing mutant HBGF-1  (glutamic  acid instead of lysine at 
amino acid position 132;  p132E)  was  constructed as  follows.  The Eco 
RI/Hind HI fragment of HBGF-1 eDNA clone 1 (21) was subcloned into 
M13mplS. Single-stranded template was prepared and used for oligonucleo- 
tide-directed in vitro mutagenesis.  Double-stranded DNA was transformed 
into E.  coil TG-1 cells and the resultant plaques were screened by MI3 
dideoxy sequencing.  The mutated HBGF-1 eDNA was transferred into the 
expression vector pKK223-3  using the original Eco RI and Hind m  sites. 
Production and Purification of  Recombinant Proteins 
Recombinant plasmids pREC  or p132E were introduced into the/aci  Q- 
bearing  Eacherichia  coil strain JMI03.  Cultures of JM103  bearing the 
recombinant  plasmids were grown with shaking at 37°C in Luria broth con- 
taining 100/~g/ml ampicillin. A fresh overnight culture was diluted and 
grown  until  the  As~o reached  ,x,0.2,  at  which  point  isopropylthio-/3- 
galactoside was added to 1 raM. Cells were collected by centrifugation and 
frozen at -80°C for subsequent growth factor purification. 
The frozen cell pellets from 2-liter cultures were resuspended in 50 ml 
of 10 mM Tris-HCl, pH 7.5, 5 mM EDTA, 50 mM glucose. A fresh solution 
of hen egg lysozyme in the same buffer was added to 10/~g/ml.  The cells 
were mixed at 4°C for 45 rain. The viscous lysate was sonicated at maxi- 
mum intensity using a large probe and four 20-s pulses of a Heat Systems 
W-380 sonicator.  The lysate was clarified by centrifugation at 6,000 g for 
15 rain at 4°C.  The supernatant was diluted to 100 ml with 50 mM Tris- 
HC1, pH 7.5, 10 mM EDTA and incubated with 20 ml of hydrated heparin- 
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batchwise using a sintered glass funnel and successive washes of the same 
buffer containing 0, 0.1, 0.5, 0.65, and 1.5 M NaCI. 
The wild-type recombinant HBGF-I  eluted with the 1.5 M NaC1 wash. 
The mutant was eluted with the 0.5 M NaC1 wash. Although the wild-type 
protein was essentially pure after heparin-Sepharose chromatography,  the 
mutant I-IBGF-1 constituted only 10-20% of the 0.5 M NaCI wash.  Both 
preparations were purified to >95 % purity using reversed-phase  HPLC (4). 
The reversed-phase  purified material was used for all reported studies. 
Characterization of  Recombinant Proteins 
All  preparations of purified recombinant human wild-type and mutant 
HBGF-1 were analyzed by SDS-PAGE, amino acid analysis, amino terminal 
sequencing,  peptide mapping, and amino acid sequencing of the peptide en- 
compassing the mutated residue.  Protein concentrations were determined 
by amino acid analysis. Aliquots of wild-type and mutant HBGF-1 were sub- 
jected to electrophoresis using the SDS-PAGE system of Laemmli (26). A 
15%  acrylamide, 0.4%  N,N'-methylenebisacrylamide solution was poly- 
merized in a Hoefer mini-gel apparatus and electrophoresis was carried out 
at a constant 200 V. Protein was visualized by staining the gel with 0.1% 
Coomassie blue R-250 in 50% methanol, 10% glacial acetic acid, and de- 
staining with 9% glacial acetic acid, 5 % methanol. Samples for amino acid 
analysis were hydrolyzed  with argon-purged,  constant boiling 6 N HCI at 
115"C for 18 h using a Pico-Tag workstation (Waters Associates,  Milford, 
MA). Amino acids were derivatized with phenylisothiocyanate  and sepa- 
rated with a  PTC analyzer (model  130A; Applied Biosystems,  Inc.).  A 
Waters 840 system was used for data collection and reduction.  Amino acid 
sequences were established using a protein sequencer (model 477A; Ap- 
plied Biosystems,  Inc.) using modified  Edman chemistry and an on-line 
model 120A PTH analyzer.  Peptide mapping of recombinant protein after 
digestion with endoproteinase Asp-N at a  1:25 ratio of enzyme to protein 
in 50 mM Na2HPO4, pH 8.0, 37"C for 18 h was performed using a micro- 
bore HPLC system (model 130A; Applied Biosystems, Inc.). The appropri- 
ate peptides were subjected to amino acid sequence analysis to establish the 
fidelity of expression of the wild-type and mutant I-IBGF-1 vectors. 
Stability Studies 
Metabolically labeled recombinant  proteins were prepared by growing bac- 
terial cultures as described above until the A550 reached *0.4,  at which 
point the cells were collected by centrifugation. They were resuspended in 
98.5%  M9  minimal  medium/1.5%  Luria  broth  and  [3H]leucine  (140 
Ci/mmol) was added to 45 i~Ci/ml. Cells were grown with shaking for 30 
rain, and then for an additional 4 h in the presence of 1 mM isopropylthio-B- 
gaiactoside.  Ceils were collected and growth factors pro/fled as described 
above. The purified,  labeled growth factors were incubated for 48 h at 370C 
in the presence of media (DMEM containing 10% calf serum) that had been 
conditioned for 48 h by NIH 3T3 cells. The growth factor-containing  media 
was analyzed by SDS-PAGE and autoradiograpby. 
Mitogenic Assays 
The mitogenic activities of wild-type and mutant recombinant HBGF-1 
were determined by measuring their ability to stimulate DNA synthesis in 
NIH 3T3 cells and to support the proliferation of human umhilical vein en- 
dothelial cells.  DNA synthesis  was determined by measuring the amount 
of [3H]thymidine  incorporated into cells.  Briefly,  NIH  3T3  cells were 
seeded into 48-well plates and grown to near confluence in DME containing 
10% calf serum. The cells were serum starved (DME, 0.5%  calf serum) 
for 24 h. Mitogens were added to the wells and incubated for 18 h. The 
cells were pulsed with 0.5 ttCi/ml of [3H]thymidine (25 Ci/mmol) for 4 h. 
The cells were rinsed with PBS, fixed with 10% q'CA, rinsed with PBS, and 
then solubilized  with 0.5 N  NaOH.  Incorporation of [3H]thymidine  into 
acid-insuluble material was determined by scintillation  counting.  All assays 
were performed in triplicate. 
Human umbilical vein endothelial cells were  provided by T.  Maciag 
(American Red Cross, Rockville,  MD).  They were maintained on fibro- 
nectin-coated plates (2 #g/era  2) in medium 199 supplemented with 10% 
(vol/vol) heat-inactivated FBS, 1× antihiotic-antimycotic, 10 U/mi hepat/n, 
and 10 ng/ml human recombinant HBGF-1. For growth assays, cells were 
seeded in 24-well plates at 2,000 cells/well  in medium 199 supplemented 
as above with the exception of HBGF-1. The indicated amounts of wild-type 
or mutant HBGF-1 and heparin were added to the wells.  The media was 
changed ever other day. After 7 d in culture, cells were trypsinized and 
counted using a hemocytometer. 
Competition for Binding and Cross-Linking to Cell 
Surface Receptors 
Bovine brain-derived HBGF-1 (4) was labeled with 125I  using immob'flized 
lactoperoxidase  and biologically  active, labeled protein was isolated using 
heparin-Sepbarose as described (16). Confluent NIH 31"3 cells in 24-well 
plates were serum starved for 24 h before binding experiments in DME con- 
taining 0.5 % calf serum. The cells were washed and incubated with DME 
containing 5 U/mi heparin, 0.5% BSA, and 25 mM Hepes, pH 7.2 (binding 
buffer) at room temperature for 20 rain. The ceils then were incubated with 
125I-HBGF-1 and unlabeled wild-type or mutant HBGF-1 in the presence of 
5 U/ml beparin as indicated in the figure legend.  The cells were incubated 
on ice for 90 rain. The plates were aspirated and washed four times with 
binding buffer. The cells were then incubated for 20 rain at 4°C with 1 ml 
of 0.3 mM disuccinimidyl suberate in PBS. The cross-linker was then aspi- 
rated off and the reaction quenched by adding 2.0 M Tris-HCl, pH 8.0. The 
cells were washed with PBS, scraped from the plates and pelleted for 10 s 
at 15,000 g. The pellets were extracted with 100 td of 50 mM Tris,  1 mM 
EDTA, 200 mM NaCI,  1.0% Triton X-100, 0.1 mM phenylmethylsulfonyl 
fluoride,  pH 7.5 for 20 rain at 4°C.  The extracts were centrifuged for 10 
rain at 15,000 g. The supernatants were removed and mixed with an equal 
volume of Laemmli sample buffer for SDS-PAGE analysis. 
Stimulation of  Protein IJn,osine  Kinase Activity 
NIH 3T3 cells were grown to confluence  in 100 mm dishes and serum 
starved as described above. The cells were then exposed to diluent 1.0, or 
10 ng/ml of wild-type or mutant HBGF-1 for 10 rain at 370C. The cells were 
washed once with cold PBS then lysed in buffer containing 10 mM "Iris, 
50 mM NaC1, 5 mM EDTA, 50 mM NaF, 30 mM sodium pyrophospbate, 
100 tiM sodium orthovanadnte,  1.0% Triton X-100, I mM phenylmethylsul- 
fonyl fluoride,  pH 7.4. The ceils were scraped from the plates, vortexed, 
and incubated on ice for 10 min. Lysates were clarified by centrifugation 
at 10,000 g for 10 min at 4 °C and the supernatants were mixed with an equal 
volume of  2x Laemmli sample buffer. Samples  (normalized to cell num- 
ber) ware subjected to PAGE in the presence of SDS.  The proteins were 
transferred to nitrocellulose and immunoblotted with anti-phosphotyrosine 
antibodies as described (15). The blots were incubated with 12SI-protein  A 
and phosphotyrosine-containing  proteins were visnaliTed by autoradiogra- 
phy. In some experiments the initial cell lysates were incubated with a pre- 
bound anti-phospholipase C-7 antibody/protein  A-Sepharose complex (31) 
for 90 min at 4oc. The beads were washed with 20 mM Hepes, 0.1% Triton 
X-100, 150 mM NaCI,  10% glycerol, pH 7.5. Immunoprecipitated proteins 
were eluted from the beads with 2x Laemmli sample buffer and subjected 
to PAGE and Western blotting with anti-phosphotyrosine antibodies as de- 
scribed above. 
RNA Gel Blot Analysis 
NIH 3T3 cells were incubated for 48 h in DME/0.5 % FCS and then either 
left unstimulated or stimulated  with wild-type or mutant HBGF-1 for the 
indicated times.  Cells were harvested, total RNA was prepared (17), and 
10 tzg of each sample was separated by electrophoresis on 1.2% agarose gels 
containing formaldehyde.  The gels were stained with ethidium bromide 
photographed to verify that each lane contained an equal amount of un- 
degraded ribosomal RNA. RNA was electroblotted onto Zetabind nylon 
filters and cross-linked by UV irradiation. The restriction fragments used 
and source of the DNA probes were as follows:  (a) c-los,  2.8-kb Nco I/ 
Xho I fragment of pc-fos-l; American Type Culture Collection, Rockville, 
MD; (b) c-jun, 1.5-kb Hind IR/Bam HI fragment of ph-cJ-1; girl of P. An- 
gel, University of Caiifornia, La Jolla, CA; (c)c-myc, 1.4-kb Sst I fragment 
of pHSR-1; ATCC; (d) glyceraldehyde  3-phosphate dehydrogenase,  0.8-kb 
Pst I/Xba I fragment of pHcGAP; ATCC. The probes were labeled with 
[32p]dCTP (3,000 Ci/rnmol) using a random primer labeling kit. Hybrid- 
ization and filter washes were as described (17). Blots were exposed to Ko- 
dak XAR5 film at -70°C. 
Transfection of NIH 3T3 Cells with HBGF-1 
Eukaryotic Expression Plasmids 
NIH 3T3 cells in 100 mm dishes were transfected with plasmid DNA by 
the calcium phosphate  precipitation method (44). Cells were incubated with 
either 1 pg of pSV2 neo (41) or co-transfected  with a mixture 0:10/~g) of 
pSV2 neo and either HBGF-1 wild-type expression vector (p267) or I-IBGIL1 
mutant expression vector (p268).  The plasmid p267 is described in Jaye et 
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Figure 1. Stimulation of DNA synthesis in NIH 3"1"3 cells by wild-type and mutant HBGF-1. Cells were grown to near confluence and 
serum starved for 24 h as described in Materials and Methods. Cells were treated with the indicated concentrations of wild-type (e) or 
mutant (A) I-IBGF-1,  incubated for 18 h, and then pulsed with 0.5/~Ci of [3H]thymidine/ml  for 4 h. The cells were harvested and incorpo- 
ration of radioactivity was determined. Both wild-type and mutant HBGF-1 were assayed in the presence of 0 (A), 5 (B), or 50 U/ml 
heparin (C). 
al. (23); p268 was constructed by replacing the 297nt Pvu lI/Bgl 1I fragment 
of p267 (encoding amino acids 38-155) with the corresponding region from 
the prokaryotic expression plasmid pE132 using standard subeloning meth- 
ods. Cells were split to 10 dishes and transfeeted colonies were selected by 
incubating the cells in DME, 10% calf serum containing 500/~g/ml Geneti- 
tin. The media was changed every 3--4 d. After 4 wk, transfected colonies 
were analyzed for HBGF-I expression by Western blot analysis using rabbit 
polyclonal  HBGF-l-specifie antibodies and  t~I-protein A  as  described 
above. 
Results 
Heparin-binding Properties of  HBGF-I Mutant p132E 
A drastic reduction in the apparent affinity of HBGF-1 con- 
taining glutarnic acid in place of lysine at position 132 was 
observed during the purification of the recombinant proteins 
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Figure 2.  Ability of wild-type and mutant HBGF-1 to stimulate 
growth  of human  umbilical  vein  endothelial  ceils.  Cells  were 
seeded and cultured as described in Materials and Methods. Cell 
number after 7 d in culture in the presence of the indicated concen- 
trations of wild-type (o/e) or mutant (zx/&) I-IBGF-I in the ab- 
sence (o/zx) or presence (e/a) of 50 U/ml heparin is shown. 
from the Escherichia coli lysates.  Recombinant wild-type 
HBGF-1  from  E.  coli lysates  can  be  purified  to  near 
homogeneity with a single heparin-Sepharose step. The pro- 
tein binds the immobilized heparin during extensive washing 
with 0.5 and 0.65 M NaCl-containing buffers and is eluted 
with a single step of 1.5 M NaCl-containing buffer. In con- 
trast,  heparin-Sepharose  affinity-based  chromatography 
could not be used as a single purification step for the mutant 
HBGF-1. The mutant protein binds immobilized heparin in 
the presence of 0.1 M NaC1 but was eluted during the 0.5 M 
NaC1 wash. Both wild-type and mutant HBGF-1 (1.5 and 0.5 
M NaC1 eluates, respectively) could be purified to apparent 
homogeneity using reversed-phase HPLC. Detailed analysis 
of the apparent affinities of the two purified proteins for im- 
mobilized heparin-Sepharose using relatively shallow, linear 
NaC1  gradients  indicated that the mutant  I-IBGF-1 eluted 
with 0.45 M NaC1 whereas wild-type required 1.1 M NaC1 
to be eluted (data not shown). For all of the assays described 
below we used reversed-phase HPLC purified wild-type or 
mutant HBGF-1. Protein concentrations were determined by 
amino acid analysis of preparations that had been shown to 
be the desired HBGF-1 form by peptide mapping and amino 
acid sequence analysis (data not shown). 
Mitogenic Properties of  HBGF-I Mutant p132E 
The ability of the I-IBGF-1 mutant to stimulate mitogenesis 
was  compared to that of the wild-type protein using two 
different assays.  In the first, the ability of the two proteins 
to stimulate DNA synthesis in NIH 3T3 cells as measured 
by [3H]thymidine incorporation was examined. The assays 
were conducted over a broad range of I-IBGF-1 and heparin 
concentrations. Two important points can be made from the 
data in Fig.  1. One, the wild-type HBGF-1 has a dramatic 
requirement for the presence of heparin for optimal mito- 
genie activity and, two, the mutant HBGF-1 is significantly 
less potent than wild-type protein in the presence of added 
heparin. As can be seen in Fig. 1, the maximal difference in 
mitogenic potency was observed in the presence of 5 U/ml 
heparin (~30-fold). Little difference (approximately three- 
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Growth factor  concentration  (ng/ml) 
0  0.1  0.5  1  5  10 
GLU132 HBGF-1  1.6  1.6  1.3  1.2  1.7  1.4 
Wild-type HBGF-1  1.7  2.0  1.9  2.9  12.6  16.6 
fold) between the wild-type and mutant protein is seen in the 
absence of added heparin because of the relative lack of 
mitogenic activity of wild-type human recombinant HBGF-1 
in the absence of heparin. The possibility that the reduced 
mitogenic activity of the mutant HBGF-1 is related directly 
to its reduced apparent affinity for immobilized heparin is 
supported by the observation that the difference in the mito- 
genic potency between the wild-type and mutant protein is 
reduced to '~18-fold in the presence of 50 U/ml heparin. 
In the second mitogenesis assay the abilities of the wild- 
type and mutant proteins to support the proliferation of hu- 
man umbilical vein endothelial cells were compared.  The 
results shown in Fig. 2 are consistent with those described 
above in that they demonstrate a dramatic heparin require- 
ment of  the wild-type HBGF-1 for biological activity and that 
the mutant HBGF-1 is not able to support ceil proliferation 
to the same extent as the wild-type protein. These experi- 
ments were conducted in the presence of 50 U/ml heparin 
and the endothelial cells were seeded in the presence of 10 
ng/ml wild-type HBGF-1.  When growth assays were con- 
ducted in the presence of 5 U/ml heparin without wild-type 
protein during the seeding, mitogenic deficiencies of  the mu- 
tant protein were more pronounced (Table  I).  The results 
shown in Fig. 3 demonstrate that the reduced mitogenic ac- 
tivity of the mutant HBGF-1 does not appear to be the result 
of any increased susceptibility of the protein to proteolytic 
digestion by components in serum or the conditioned media 
of NIH 3T3 cells. 
Receptor-binding Activity of  HBGF-I Mutant p132E 
The results presented above are consistent with the observa- 
Figure 3. Analysis of the relative stability 
of wild-type and mutant HBGF-I in NIH 
3T3  cell-conditioned media. The wild- 
type and  mutant proteins were labeled 
and purified as described in Materials and 
Methods. The proteins were incubated in 
the presence of  NIH 3T3 ceil-conditioned 
media for48 h at 37°C and then subjected 
to SDS-PAGE. The gels were dried and 
labeled proteins visualized  by autoradiog- 
raphy. Lane 1 contains wild-type HBGF-I 
and lane 2 mutant I-IBGF-1. The apparent 
molecular weights of both proteins are 
identical to that of HBGF-1 before incu- 
bation. 
tions of Harper and Lobb (19) using bovine brain-derived 
HBGF-1  selectively methylated at lysine 132,  although the 
magnitude of the reduction in rnitogenic potency (,~30-fold 
for 3T3 cell assay) as compared with the ,,o4-fold decrease 
reported by Harper and Lobb (19) is significantly greater. 
They also reported reduced receptor-binding activity for the 
modified protein. We examined the abilities of the wild-type 
and mutant recombinant HBGF-1  to compete with ~SI-la- 
beled bovine HBGF-1  for binding to cell surface receptors 
on NIH 3T3 cells at a concentration of added heparin (5 U/ 
rnl) where the difference in mitogenic potencies of the two 
proteins was greatest. 
The receptor-binding activity of the mutant HBGF-1 was 
established by competition for cross-linking of ~2SI-HBGF-1 
to 150,000- and 130,000-Mr proteins present on the surface 
of NIH 3"1"3 cells (16). The results shown in Fig. 4 demon- 
strate that the mutant I-IBGF-1 is similar to wild-type protein 
in its ability to compete for receptor-ligand cross-linking. 
The functional consequences of I-IBGF-1 binding to its cell 
surface receptor include stimulation of protein tyrosine ki- 
nase activity (8, 15, 20) including phosphorylation of phos- 
pholipase C-  7 (6). Fig. 5 A demonstrates that both wild-type 
and mutant HBGF-1 are able to increase the phosphotyrosine 
content of 150,000-,  90,000-,  and 70,000-Mr  proteins and, 
to a  lesser extent, proteins with lower relative molecular 
masses as judged by Western blot analysis with phospho- 
tyrosine-specific  antibodies. The dose response and extent of 
activation is similar for the two forms of the growth factor. 
Stimulation of the phosphotyrosine content of phospholipase 
C-'y was examined  by anti-phosphotyrosine  Western blot anal- 
ysis of 3T3 cell lysates after immunoprecipitation using anti- 
bodies that recognize phospholipase C-3,. Fig. 5 B demon- 
strates ths" mutant HBGF-1  shares with wild-type HBGF-1 
the ability to stimulate tyrosine phosphorylation of phospho- 
lipase C-  7. These data regarding stimulation of tyrosine ki- 
nase activity by wild-type and mutant HBGF-1 are in good 
agreement with the receptor-binding data described above 
but do not provide insight into the functional basis for the 
relatively poor mitogenic capacity of this I-IBGF-1 mutant. 
Protooncogene Induction by V~ld-l)~pe and 
Mutant HBGF-1 
The results described above indicate that the functional  prop- 
erties of the mutant HBGF-1 associated with events that oc- 
cur at the cell surface (i.e., receptor-binding and tyrosine ki- 
nase activation) are normal with respect to those of  wild-type 
HBGF-1.  In addition to tyrosine kinase activation, another 
early response to HBGF-1 receptor-binding is the elevation 
ofprotooncogene mRNA levels (17). To determine the effect 
of wild-type and mutant HBGF-1 on protooncogene expres- 
sion, NIH 3T3 cells were serum starved and then either left 
unstimulated or stimulated with 10 ng/ml wild-type or mu- 
tant HBGF-1. Heparin (5 U/nil) was also added to the cells 
receiving  growth  factor.  Ceils  were  collected  at  various 
times after stimulation, RNA was prepared,  and levels of 
c-fos, c-jun, c-myc, and glyceraldehyde  3-phosphate dehydro- 
genase mRNA (as a control for the amount of RNA loaded 
in each lane) were assayed by RNA gel blot analysis. Wild- 
type and mutant HBGF-1 increased protooncogene mRNA 
levels to a similar degree; maximal levels were observed at 
30 rain (c-fos,  c-jun) or 2 h (c-myc) after stimulation (Fig. 
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cogene expression. Since the mitogenic differences between 
the wild-type and mutant HBGF-1 are more pronounced at 
lower growth factor concentrations, we also stimulated cells 
with 0.5,  1.0, 5.0, and 10 ng/ml wild-type and mutant growth 
factor (again in the presence of heparin). At all four concen- 
trations used, the wild-type and mutant HBGF-1 were simi- 
lar in their ability to induce c-fos mRNA expression (Fig. 7). 
Figure 4. Ability of wild-type and mutant HBGF-I to compete with 
t25I-labeled bovine  HBGF-I  for  cross-linking  to  150,000-  and 
130,000-mol wt cell surface receptors.  NIH 3T3 cells were incu- 
bated with  1 ng/ml bovine  ~25I-HBGF-1 and either  0.5, 1.0, 5.0, 
10.0, or 50.0 ng/ml of wild-type (lanes 1-5) or mutant (lanes 6-10) 
human recombinant I-IBGF-1  in the presence of 5 U/ml heparin. Af- 
ter incubation, the cells were treated with cross-linking reagents as 
described in Materials and Methods. The apparent molecular weights 
of  cross-linked species were determined after SDS-PAGE and auto- 
radiography.  The  positions  of  two  cross-linked  150,000-  and 
130,000-tool wt species, which correspond to the known apparent 
molecular weights of HBGF receptors,  are indicated with arrows. 
Overexpression of VCild-7}~pe and Mutant HBGF-1 in 
Transfected NIH 313 Cells 
It was demonstrated previously that overexpression of wild- 
type HBGF-1 in transfected Swiss 3T3 cells resulted in cells 
with  an  elongated,  transformed morphological phenotype 
that  grew  to higher  saturation  densities  (23).  This  trans- 
formed phenotype occurred even though the HBGF-1 poly- 
peptide was not detectable in the conditioned media of these 
cells. We have shown that the mutant HBGF-1 is not a potent 
mitogen  although  it  can  bind  receptor  and  initiate  early 
events associated with mitogenic signal transduction. To in- 
vestigate whether the  intracellular  function  of the  mutant 
HBGF-1 was altered, we examined the ability of this protein 
to induce a  transformed phenotype in NIH 3T3 cells. Cells 
were either transfected with a plasmid conferring neomycin 
resistance  or  co-transfected with  the  neomycin resistance 
plasmid and wild-type or mutant HBGF-1 expression vectors. 
Fig. 8 shows the results of Western blot analysis of trans- 
fected cell  lysates using  HBGF-l-specific antibodies.  The 
Western blot analysis was normalized to cell number and 
provides the basis for our designation of relatively high or 
low levels of HBGF-1 expression. The results shown in Fig. 
9 demonstrate that cells expressing a high level of wild-type 
HBGF-1 (Fig. 9 B) and to some extent a low level of wild- 
Figure 5. Stimulation of protein tyrosine ki- 
nase  activity  by  wild-type  and  mutant 
HBGF-1. (A) Serum starved NIH 3T3 cells 
were either (lane 1) unstimulated or treated 
with 5 U/ml heparin and (lane 2)  1 ng/lrd 
wild-type;  (lane  3)  10  ng/ral  wild-type; 
(lane  4)  1 ng/ml  mutant;  or  (lane 5)  10 
ng/ml  mutant  HBGF-1. The  cells  were 
processed  as  described  in  Materials  and 
Methods  and  phosphotyrosine-containing 
proteins were visualized using antiphospho- 
tyrosine antibodies and 125I-protein  A. The 
arrows indicate the positions  of 150,000-, 
90,000-, and 70,000-mol wt proteins whose 
phosphotyrosine  content  are increased  by 
the addition of wild-type or mutant HBGF-I. 
(B) Cells were incubated as in A with the 
exception that cell lysates were immunopre- 
cipitated with anti-phospholipase C-3' anti- 
bodies before Western blot analysis with an- 
ti-phosphotyrosine  antibodies.  Cells  were 
either 0ane I) unstimulated or treated with 
(lane 2) 10 ng/ml wlld-typ¢, or (lane 3) 10 
ng/ml mutant HBGF-1. The arrow shows the 
position of a 150,000-mol wt protein whose 
phosphotyrosine  content  is  increased  by 
treatment with wild-type or mutant HBGFd. 
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mRNA levels. Serum starved NIH 3T3 cells were either left un- 
stimulated  or treated with heparin (5 U/ml) and 10 ng/ml wild-type 
(wt) or mutant (nat) HBGF-I for the indicated time periods. RNA 
was prepared and used for RNA gel blot hybridization  using the ra- 
diolabeled DNA probes indicated on the left side (GAPDH, glycer- 
aldehyde 3-phosphate dehydrogenase). The upper and lower tick 
marks on the left side of each panel represent the positions of 28 
and 18S rRNA, respectively. 
stoichiometric modification of lysine residue 132 (using the 
1-154 numbering system for full-length HBGF-1). It was sug- 
gested that modification of this residue, which is conserved 
in all HBGF-1 and I-IBGF-2 sequences reported to date, was 
responsible for the reduced apparent affinity  for immobilized 
heparin,  the reduced mitogenic capacity, and the reduced 
receptor-binding activity of  the modified  protein. The results 
presented here using site-directed mutagenesis to address 
the role of lysine 132 on the functional properties of HBGF-1 
are in general agreement with the conclusions of Harper and 
Lobb (19).  Specifically, substitution of lysine 132 for glu- 
tamic acid reduces the apparent affinity of the recombinant 
protein for immobilized heparin (elutes at 0.45 M NaC1 com- 
pared with 1.1 M NaC1 for wild-type) and significantly re- 
duces the mitogenic potency of the growth factor. The re- 
duced mitogenic potency may be a direct consequence of the 
reduced apparent affinity of the mutant I-IBGF-1 for heparin 
since  it has  been demonstrated that the class  1  heparin- 
binding growth factors in general (29) and human HBGF-1 
in particular (22, 43) are dependent on the presence of  hepa- 
rin for optimal biological activity. 
Our  results do not support the notion that the reduced 
mitogenic capacity of HBGF-1 containing glutamic acid in 
place of lysine at position 132 is due to reduced binding to 
cell surface receptors.  The receptor-binding properties of 
the mutant I-IBGF-1 are not distinguishable from those of the 
wild-type protein  as judged by cross-linking experiments 
(see Fig. 4). In addition, the mutant HBGF-1 is able to in- 
duce the same pattern of tyrosine kinase phosphorylation as 
is the wild-type protein (see Fig. 5) and can induce proto- 
oncogene expression (see Fig. 6). The majority of the studies 
presented here utilize a heparin concentration of 5 U/ml; the 
concentration where maximal difference between the mito- 
genie activity of wild-type and mutant HBGF-1 was observed 
in the 3T3 cell thymidine incorporation assay. It should be 
noted that in the absence of heparin,  the mutant HBGF-1 
competes poorly with labeled wild-type HBGF-1  in cross- 
type HBGF-1  (Fig. 9 D) have acquired a more polar, elon- 
gated phenotype characteristic  of transformed  3I'3  cells. 
This phenotype is not seen in cells expressing neomycin re- 
sistance alone (Fig. 9 A) or in cells expressing relatively high 
levels of mutant I-IBGF-1 (Fig. 9 C). It should be noted that 
we have not been able to detect HBGF-1  immunoreactivity 
in the media conditioned by these cells and that the cells ex- 
pressing relatively high levels of  wild-type I-IBGF-1 show en- 
hanced growth in soft agar relative to untransfected cells or 
cells expressing high levels of the mutant I-1BGF-1 (data not 
shown). These results are consistent with the results of the 
mitogenic assays described above which demonstrate that 
the growth-promoting activity of the mutant HBGF-1 is rela- 
tively low when compared to the wild-type protein. 
Discussion 
The experiments described in this report were initiated as a 
result  of  the  chemical  modification  studies  of  HBGF-1 
reported by Harper and Lobb (19). They demonstrated that 
reductive  methylation  of  I-IBGF-1  resulted  in  selective, 
Figure 7. Effect  of different  concentra- 
tions of  wild-type  and mutant HBGF-1 
on c-fos  mRNA levels. Serum starved 
NIH 3"1"3 cells were either left un- 
stimulated or treated with heparin (5 
U/ml) and (A) 0.5 ng/ml, (B) 1.0 ng/ 
~, (C) 5.O ng/~, (D) 10 ngrra wUd- 
type (wt) or mutant (mt) HBGF-1 for 
the indicated time periods. RNA was 
prepared and used for RNA gel blot 
hybridization using  the c-fos DNA 
probe (upper panels) or glyceralde- 
h)~ 3-phosphate  deh)drogemse  DNA 
probe (lower panels). 
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HBGF-1 in NII-I 3T3 cells transfect- 
ed with wild-type  or mutant HBGF-1 
expression plasmids. NIH 31"3 cells 
were  transfected  as  described  in 
Materials and Methods. The figure 
shows the relative levels of  HBGF-1 
immunoreactivity  present in lysates 
of cells transfected with wild-type 
HBGF-1 (lane 1, clone producing 
relatively  high  level of HBGF-1; 
lane 3, clone producing relatively 
low level of HBGF-1) normal NIH 
3T3 cells (lane 2), cells transfected 
with pSV2neo alone (lane 4), and 
cells transfected with mutant I-IBGF-1 (lane 5). For each cell type, 
106 cells were lysed with 1 ml of2x Laemmli sample buffer and 
a 60-#1 aliquot was used in the Western blot. 
linking assays (data not shown). In addition, whereas the ap- 
parent affinity of the mutant HBGF-1 for immobilized hepa- 
fin is reduced, it does bind at ionic strengths (i.e., ~0.5 M 
NaC1) that exceed those known to be physiologic. Thus, the 
data presented here indicate that the mutant can utilize the 
presence of heparin to restore some (i.e., receptor-binding, 
tyrosine kinase activation, and protooncogene induction) but 
not  all  (i.e.,  stimulation  of  [3I-I]thymidine  incorporation 
into DNA and endothelial cell proliferation) of the activities 
of the wild-type protein. Similarly, it is of interest that the 
wild-type protein competes with labeled HBGF-1 for recep- 
tor-binding and induces protooncogene expression at similar 
concentrations in the presence or absence of added heparin 
yet it requires added heparin in order to promote DNA syn- 
thesis and cell proliferation (Figs.  1, 2, 4, and 6; and data 
not shown). Thus, the relatively poor mitogenic activity of 
the mutant protein may be related to its reduced apparent 
affinity for heparin.  The data presented here demonstrate 
that "high" affinity receptor-binding, activation of tyrosine 
kinase  activity,  tyrosine phosphorylation of specific sub- 
strates, and induction of protooncogene expression may be 
necessary but are not, by themselves, sufficient to sustain a 
mitogenic response to the presence of  HBGF-1. These results 
are consistent with the observations of Escobedo and Wil- 
liams (12) who showed by site-directed mutagenesis of the 
PDGF receptor and cDNA transfection that mutants could 
be constructed that were responsive to PDGF with respect 
to receptor tyrosine kinase activation and increased phos- 
phatidylinositol turnover but did not elicit a mitogenic re- 
Figure 9. Morphology of NIH 3T3 cells transfected with wild-type or mutant HBGF-1 expression plasmids. The figure shows micrographs 
of the same NIH 3"1"3  cells analyzed by Western blot analysis in Fig. 8. A shows cells transfected with pSV2neo only and B-D show cells 
co-transfected with pSV2neo and expression vectors for wild-type (B and D) and mutant (C) HBGF-1. The cells shown in B correspond 
to those expressing relatively high levels of HBGF-1 (Fig. 8, lane 1 ), whereas those shown in D correspond to those expressing relatively 
little HBGF-1 (Fig. 8, lane 3). 
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similar methods to generate a system where the mutant re- 
ceptor could mediate an increase in c-los expression in re- 
sponse to PDGF but not actin reorganization or mitogenesis. 
The mitogenic deficiencies of the mutant I-IBGF-1 may be 
due to reduced biological stability in tissue culture medium, 
reduced binding to cell surface proteoglycans, an altered in- 
tracellular stability, and/or an altered affinity for an intracel- 
lular receptor or binding protein. It has been established that 
the presence of heparin protects I-IBGF-1 from thermal and 
proteolytic inactivation (28,  37).  In addition, it has been 
shown that 125I-labeled I-IBGF-1 is relatively insensitive to 
lysosomal degradation after receptor-mediated endocytosis 
(14). There is no obvious difference in the susceptibility of 
wild-type and mutant HBGF-1 to proteolytic cleavage by the 
conditioned media of NIH 3T3 cells cultured in the presence 
of 10% calf serum. However, the relative resistance of wild- 
type and mutant I-IBGF-1 to proteolytic modification in the 
presence of  target cells or after receptor-mediated endocyto- 
sis has not been established. It is also possible that the mu- 
tant protein is more susceptible than the wild type to nonpro- 
teolytic inactivation. Further studies should reveal whether 
the altered activities of the mutant I-IBGF-1 are a  conse- 
quence of its reduced apparent affinity for heparin. 
In summary, the data presented here demonstrate that the 
various functions of HBGF-1 can be dissociated at the struc- 
tural level. The observation that site-directed mutagenesis 
can be used to produce recombinant proteins with "normal" 
receptor-binding activity and reduced mitogenic activity in- 
dicates that similar methods could be used to produce potent 
antagonists of HBGF-1. More importantly, these results indi- 
cate that it may be possible through structure-function anal- 
ysis and site-directed mutagenesis to generate mutants that 
retain  certain  (i.e.,  chemotactic,  mitogenic,  or  heparin- 
binding) but not other biological functions characteristic of 
the wild-type protein. Finally, whereas the data presented on 
the receptor-binding and tyrosine kinase activation proper- 
ties of the p132E  mutant demonstrate that a lysine residue 
at this position is not critical for these functions, it is still 
possible that methylation of a lysine at this position could 
lead to reduced receptor-binding activity of HBGF-1  (19). 
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